Literature DB >> 7497580

Stability of the i.v. and oral formulations of etoposide in solution.

S P Joel1, P I Clark, M L Slevin.   

Abstract

Etoposide is a widely used cytotoxic drug that requires complex formulation for both the i.v. and oral preparation to ensure drug stability. Data on the stability of the i.v. formulation when diluted in infusion fluids are contradictory, and there is little information on the stability of the oral preparation in gastric or intestinal fluids. The stability of both i.v. and oral etoposide was therefore evaluated in the present investigation. The stability of the i.v. preparation was investigated across a range of concentrations in infusion fluids, being determined by regular sampling for high-performance liquid chromatography (HPLC) analysis and by visual inspection. The stability of the oral preparation was studied in both artificial gastric and intestinal fluids, again with regular sampling for HPLC analysis, and the influence of pH, concentration and the addition of ethanol and bile salts on oral stability was determined. The i.v. preparation showed a marked decrease in stability with increasing drug concentration, but stability was additionally reduced in i.v. bags regularly sampled with a syringe and needle as compared with bags that were inspected visually only (minimal stability in sampled bags, 24 h at 0.5 mg/ml and 5 h at 1.0 mg/ml, as compared with 10 days and 18 h at the respective concentrations in unsampled bags). Stability was also greater at room temperature, 20-23 degrees C, as compared with 8-12 degrees C. Loss of stability was indicated by a decrease in etoposide concentration (measured by HPLC) and the appearance of a fine white precipitate, shown to be pure etoposide. Importantly, the appearance of precipitate was as sensitive as a specific HPLC assay in detecting loss of stability and was in many cases apparent when the etoposide concentration was within 5% of the starting concentration. The oral formulation also showed a marked concentration-dependent decrease in stability in artificial intestinal fluid at pH 7.5 (percentage of etoposide in solution after 2 h at 0.5, 1.0, 1.5 and 2.0 mg/ml, 94 +/- 2%, 80 +/- 5%, 68 +/- 13% and 41 +/- 9%, respectively). There was no concentration effect on stability in gastric fluid at pH 3.0, although stability was much greater at pH 3 and pH 5 as compared with pH 1 or in intestinal fluid at pH 7.5.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7497580     DOI: 10.1007/bf00685638

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide.

Authors:  J C Shah; J R Chen; D Chow
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

2.  Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.

Authors:  J H Beijnen; A U Beijnen-Bandhoe; A C Dubbelman; R van Gijn; W J Underberg
Journal:  J Parenter Sci Technol       Date:  1991 Mar-Apr

3.  In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide.

Authors:  L E Seargeant; N L Kobrinsky; C J Sus; D R Nazeravich
Journal:  Cancer Treat Rep       Date:  1987-12

4.  High-performance liquid chromatography of etoposide in plasma and urine.

Authors:  V J Harvey; S P Joel; A Johnston; M L Slevin
Journal:  J Chromatogr       Date:  1985-05-03

5.  Variable bioavailability following repeated oral doses of etoposide.

Authors:  V J Harvey; M L Slevin; S P Joel; M M Smythe; A Johnston; P F Wrigley
Journal:  Eur J Cancer Clin Oncol       Date:  1985-11

6.  The effect of dose on the bioavailability of oral etoposide.

Authors:  V J Harvey; M L Slevin; S P Joel; A Johnston; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213).

Authors:  J M van Maanen; J de Vries; D Pappie; E van den Akker; V M Lafleur; J Retèl; J van der Greef; H M Pinedo
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

8.  In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma.

Authors:  M D'Incalci; E Erba; M Vaghi; L Morasca
Journal:  Eur J Cancer Clin Oncol       Date:  1982-04

Review 9.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

10.  Stability of cisplatin and etoposide in intravenous admixtures.

Authors:  C F Stewart; E M Hampton
Journal:  Am J Hosp Pharm       Date:  1989-07
View more
  8 in total

Review 1.  Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

Authors:  Frederik E Stuurman; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

2.  High concentrated etoposide solutions, additional physical stability data in dextrose 5.

Authors:  Marine Ravey; Caroline Polo; Elise D'Huart; Jean Vigneron; Béatrice Demoré
Journal:  Eur J Hosp Pharm       Date:  2020-10-20

3.  Physicochemical stability of etoposide diluted at range concentrations between 0.38 and 1.75 mg/mL in polyolefin bags.

Authors:  Elise D'Huart; Jean Vigneron; Pauline Lider; Béatrice Demoré
Journal:  Eur J Hosp Pharm       Date:  2018-07-07

Review 4.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Pharmacological attempts to improve the bioavailability of oral etoposide.

Authors:  S P Joel; P I Clark; L Heap; L Webster; S Robbins; H Craft; M L Slevin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.

Authors:  R S de Jong; E A Slijfer; D R Uges; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions.

Authors:  Renata Rezonja; Lea Knez; Tanja Cufer; Ales Mrhar
Journal:  Radiol Oncol       Date:  2013-02-01       Impact factor: 2.991

8.  Stability of etoposide solutions in disposable infusion devices for day hospital cancer practices.

Authors:  Alison Klasen; Romain Kessari; Lionel Mercier; Cyril Valade; Jacques Grill; Romain Desmaris; Angelo Paci
Journal:  Drugs R D       Date:  2014-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.